Refine
Has Fulltext
- yes (16)
Is part of the Bibliography
- yes (16)
Year of publication
Document Type
- Journal article (15)
- Conference Proceeding (1)
Language
- English (16) (remove)
Keywords
- Neuroendocrine Tumor (2)
- Oncology (2)
- PRRT (2)
- Positronen-Emissions-Tomografie (2)
- Radionuclide Therapy (2)
- 177Lu-DOTATATE (1)
- 177Lu-DOTATOC (1)
- 18F-FDG (1)
- 18F-FDG PET/CT (1)
- 1st International Workshop (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2015 (1)
- 5IA-SPECT (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-PSMA ligand PET/CT (1)
- Antibodies (1)
- B-cell lymphoma (1)
- Cardiology (1)
- Conjugate arc therapy (1)
- EANM (1)
- FDG (1)
- FDG-PET/CT (1)
- FDG-PET/MRI (1)
- GI (1)
- Gastrointestinal (1)
- Hamburg (1)
- Highlights Lecture (1)
- Hodgkin-lymphoma (1)
- MIBG scintigraphy (1)
- Medullärer Schilddrüsenkrebs (1)
- Molecular Imaging (1)
- Myeloma cells (1)
- Myelomas (1)
- Myocardial perfusion (1)
- Neuroendocrine (1)
- Neurosciences (1)
- PET (1)
- PET/CT (1)
- Parkinson disease (1)
- Parkinson's disease (1)
- Phase-II (1)
- Physics and instrumentation (1)
- Positron emission tomography (1)
- Preclinical evaluation (1)
- Primary hyperparathyroidism (pHPT) (1)
- Prostate-cancer (1)
- RADS (1)
- Radionuclide therapy (1)
- Radiopharmacy (1)
- SPECT (1)
- SSTR (1)
- Standardisierung (1)
- Targeted therapy (1)
- Thyroid cancer (1)
- WB-DW-MRI (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [18F]FDG-PET-CT (1)
- [99mTc]-Sestamibi scan (1)
- abdominal lymph node metastases (1)
- adenocarcinoma of the lung (1)
- androgen deprivation therapy (1)
- angiogenesis (1)
- antidepressant (1)
- benzylguanidine (1)
- biosynthesis (1)
- bone marrow cells (1)
- cancer treatment (1)
- cell staining (1)
- coefficient (1)
- cognitive decline (1)
- collagens (1)
- detection rate (1)
- diagnostics (1)
- diffusion weighted MRI (1)
- diffusion weighted mri (1)
- dopamine acetylcholine (1)
- extracellular matrix (1)
- extramedullary hematopoiesis (1)
- focused surgical approach (1)
- high risk (1)
- imaging (1)
- immune check inhibitor (1)
- immune infiltration (1)
- initial experience (1)
- involvement (1)
- lesions (1)
- lung and intrathoracic tumors (1)
- lymphoma (1)
- mRNA (1)
- machine learning (1)
- malignant lymphoma (1)
- medullary thyroid carcinoma (1)
- miRNA (1)
- molecular diagnostics (1)
- multiple myeloma (1)
- multiple system atrophy (1)
- nicotinic receptors (1)
- norepinephrine transporter (1)
- organic cation transporter (1)
- parathyroid adenoma (1)
- parathyroid carcinoma (1)
- pembrolizumab (1)
- peripheral nervous system (1)
- phenethylguanidine (1)
- positron emission tomography (1)
- preoperative localization (1)
- primary hyperparathyroidism (1)
- pulmonary imaging (1)
- recurrent prostate cancer (1)
- repeat surgery (1)
- repeated surgery (1)
- response evaluation (1)
- secondary lung tumors (1)
- skin biopsy (1)
- spleen (1)
- theranostics (1)
- trachea (1)
- transcriptome (1)
- tumor burden (1)
- tumor microenvironment (1)
- tyrosine kinase inhibitor (1)
- vandetanib (1)
- whole body MRI (1)
- whole-body (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (16)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (3)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (3)
- Medizinische Klinik und Poliklinik I (3)
- Medizinische Klinik und Poliklinik II (3)
- Pathologisches Institut (3)
- Neurologische Klinik und Poliklinik (2)
- Urologische Klinik und Poliklinik (2)
- Center for Computational and Theoretical Biology (1)
- Comprehensive Cancer Center Mainfranken (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (3)
Purpose
Multiple myeloma is a hematologic malignancy originating from clonal plasma cells. Despite effective therapies, outcomes are highly variable suggesting marked disease heterogeneity. The role of functional imaging for therapeutic management of myeloma, such as positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG-PET), remains to be determined. Although some studies already suggested a prognostic value of 18F-FDG-PET, more specific tracers addressing hallmarks of myeloma biology, e.g. paraprotein biosynthesis, are needed. This study evaluated the amino acid tracers L-methyl-[11C]-methionine (11C-MET) and [18F]-fluoroethyl-L-tyrosine (18F-Fet) for their potential to image myeloma and to characterize tumor heterogeneity.
Experimental Design
To study the utility of 11C-MET, 18F-Fet and 18F-FDG for myeloma imaging, time activity curves were compared in various human myeloma cell lines (INA-6, MM1.S, OPM-2) and correlated to cell-biological characteristics, such as marker gene expression and immunoglobulin levels. Likewise, patient-derived CD138+ plasma cells were characterized regarding uptake and biomedical features.
Results
Using myeloma cell lines and patient-derived CD138+ plasma cells, we found that the relative uptake of 11C-MET exceeds that of 18F-FDG 1.5- to 5-fold and that of 18F-Fet 7- to 20-fold. Importantly, 11C-MET uptake significantly differed between cell types associated with worse prognosis (e.g. t(4;14) in OPM-2 cells) and indolent ones and correlated with intracellular immunoglobulin light chain and cell surface CD138 and CXCR4 levels. Direct comparison of radiotracer uptake in primary samples further validated the superiority of 11C-MET.
Conclusion
These data suggest that 11C-MET might be a versatile biomarker for myeloma superior to routine functional imaging with 18F-FDG regarding diagnosis, risk stratification, prognosis and discrimination of tumor subtypes.